Bortezomib induced Neuropathy Pain Model Development Service

Are you currently facing the debilitating side effects of cancer treatments, the lack of effective therapies for neuropathic pain, or challenges in developing translatable preclinical models? Our bortezomib-induced neuropathy pain model development service helps you accelerate drug discovery and develop highly effective and safe treatments through meticulously characterized animal models and advanced assessment methodologies.

Bortezomib, a proteasome inhibitor, is a cornerstone in treating multiple myeloma. However, its efficacy is often hampered by bortezomib-induced neuropathy (BIN), a severe and dose-limiting side effect affecting a significant percentage of patients. This debilitating neuropathic pain lacks effective treatments, highlighting an urgent unmet medical need. Our service provides robust preclinical models to study BIN, leveraging extensive research to understand its complex pathophysiology and accelerate the discovery of novel therapeutic interventions.

How Our BIN Pain Model Development Service Can Assist Your Project

At Creative Biolabs, our BIN pain model development service is meticulously designed to provide you with precise and actionable insights, directly addressing the critical need for effective therapies for this debilitating condition. We offer a robust platform for the comprehensive evaluation of therapeutic candidates, ensuring your project progresses efficiently from preclinical research to clinical application.

Our specific deliverables and problem-solving capabilities include:

• Precise Disease Mechanism Elucidation: We provide detailed insights into the molecular and cellular pathways underlying BIN, helping you understand the complex pathophysiology and identify novel intervention points.
• Identification of Novel Therapeutic Targets: Through our advanced screening and assessment methodologies, we assist in pinpointing specific molecules or pathways that can be modulated to prevent or alleviate BIN, guiding your drug discovery efforts.
• Robust Drug Efficacy and Safety Evaluation: Our service enables the systematic testing of your candidate compounds, providing comprehensive data on their analgesic and neuroprotective potential, as well as their safety profiles, in a highly relevant in vivo model.
• Accelerated Preclinical Development: By offering a streamlined and efficient research platform, we help reduce the time and cost associated with bringing new BIN therapies to patients, accelerating your overall drug discovery pipeline.

Discover How We Can Help - Request a Consultation.

Workflow

Our BIN pain model development service follows a structured and transparent workflow, designed to ensure clarity, efficiency, and high-quality outcomes for your project.

• Required Starting Materials:

To initiate your project, we typically require:

1. Compound Information: Detailed data on your test compounds, including chemical structure, purity, solubility, and any preliminary in vitro activity.
2. Specific Research Objectives: A clear outline of your project's goals, key questions to be answered, and desired outcomes.
3. Preliminary Data (if available): Any existing in vitro or in vivo data that can inform model selection or dosing strategies.

• Final Deliverables:

Upon completion of the service, you will receive:

1. Detailed Study Reports: Comprehensive documents outlining methodologies, results, statistical analyses, and expert interpretation of the findings.
2. Raw Data Files: All raw data generated from behavioral, electrophysiological, and histological assessments for your internal analysis and record-keeping.
3. Presentation of Key Findings: A concise summary and presentation of the most critical results, highlighting their implications for your therapeutic program.

• Estimated Timeframe:

The typical timeframe for this service ranges from 8 to 16 weeks, depending on the complexity of the model, the number of compounds to be tested, and the breadth of the assessment methodologies selected. Factors such as compound solubility, required dosing frequency, and the specific endpoints chosen can influence the overall duration.

Why Choose Us?

Choosing CBL for your BIN pain model development service means partnering with a team that combines over two decades of specialized expertise with a deep commitment to scientific rigor and translational relevance. Our unique advantages ensure that your research is built on a foundation of reliability and insight.

We pride ourselves on:

• Unparalleled Expertise: Our team comprises expert biology specialists with extensive experience in neuropathic pain research, ensuring a profound understanding of BIN pathophysiology and preclinical model development.
• Meticulously Characterized Models: Our rodent models are rigorously validated and characterized to consistently recapitulate the key clinical features of BIN, providing high fidelity and translatability to the human condition.
• Comprehensive Assessment Suite: We integrate a multidimensional array of behavioral, electrophysiological, and morphological assessments, offering a holistic view of your therapeutic candidate's impact on pain, nerve function, and pathology.
• Customized and Flexible Protocols: We understand that each project is unique. Our approach is highly collaborative, allowing for tailored study designs that precisely align with your specific research objectives and budget.
• Focus on Translational Relevance: Our models and methodologies are selected to maximize the predictive value of preclinical data, helping to bridge the gap between bench and bedside.

Experience the Advantage - Get a Quote Today.

Bortezomib-Induced Neuropathy Pain Model

At CBL, we leverage over two decades of specialized expertise to offer a comprehensive BIN pain model development service designed to meet the rigorous demands of preclinical drug discovery. Our service is built upon meticulously characterized animal models and a diverse array of advanced assessment methodologies, ensuring high fidelity and translational relevance.

• Our Approach to Model Development:

Our established models primarily utilize rodent species, particularly Sprague-Dawley rats and C57BL/6J mice, which have demonstrated consistent susceptibility to bortezomib-induced neurotoxicity. Bortezomib administration protocols are carefully optimized, typically involving a series of intraperitoneal injections on precise schedules (e.g., days 0, 3, 7, 10), to induce a dose-dependent neuropathic phenotype that closely mirrors the human condition.

To provide a holistic understanding of neuropathic pain and its underlying pathology, our service integrates a comprehensive suite of behavioral, electrophysiological, and morphological assessments:

• Behavioral Assessments: These are crucial for quantifying pain-related behaviors and include:
  • Mechanical Hypersensitivity (Allodynia/Hyperalgesia): Routinely assessed using calibrated von Frey filaments, measuring withdrawal thresholds to mechanical stimuli. This is a primary readout for neuropathic pain.
  • Cold Allodynia: Evaluated using methods like acetone evaporation or cold plate tests, though its manifestation can be dose- and strain-dependent.
  • Motor Coordination: Assessed via tests such as the rotarod, to detect any motor deficits accompanying sensory neuropathy.
  • Sensory Fiber-Specific Nociception: Utilizing specialized equipment like the Neurometer to assess the function of different nerve fiber types (C, Aδ, Aβ fibers).
• Electrophysiological Assessments: These provide objective measures of nerve function and integrity:
  • Nerve Conduction Velocity (NCV): Measurement of reduced NCV in caudal and digital nerves, indicative of axonal damage.
  • Action Potential Amplitude: Assessment of decreased action potential amplitudes, further confirming nerve fiber dysfunction.
  • Spinal Dorsal Horn Neuron Activity: Electrophysiological recordings to evaluate increased activity of wide dynamic range neurons, reflecting central sensitization.
• Morphological and Histological Assessments: These provide direct evidence of neuropathic pathology:
  • Axonal Degeneration: Microscopic examination of peripheral nerves (e.g., sciatic nerve) and dorsal roots for signs of axonal damage.
  • Mitochondrial and Endoplasmic Reticulum Damage: Histopathological analysis of DRG neurons and satellite cells to identify cellular organelle damage and vacuolization.
  • Neuronal Stress Markers: Immunohistochemical detection of markers like activating transcription factor-3 (ATF3) in DRG, indicating neuronal stress responses.
  • Intraepidermal Nerve Fiber Density (IENFD): Quantification of IENFD in skin biopsies, a sensitive biomarker for small fiber neuropathy.
• Biomarker Analysis: Measurement of key inflammatory mediators, such as proinflammatory cytokines, to understand the neuroinflammatory component of BIN.

Related Services

To further support your comprehensive drug discovery and development efforts in neuropathic pain and neurotoxicity, CBL offers a range of complementary services and model variations:

• Acute Pain Models
• Inflammatory Pain Models
• Biomarker Development & Validation
• Neuroinflammation Studies

Ready to advance your neuropathic pain research? Our team of experts is eager to discuss your project and demonstrate how our specialized services can contribute to your success.

Contact Our Team for More Information and to Discuss Your Project.